×

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

  • US 9,249,227 B2
  • Filed: 06/29/2015
  • Issued: 02/02/2016
  • Est. Priority Date: 10/21/2013
  • Status: Active Grant
First Claim
Patent Images

1. A method of alleviating symptoms in a subject having, or suspected of having, Huntington'"'"'s disease (HD), comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), wherein the antibody or fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs:

  • 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs;

    14, 15, and 16, respectively.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×